There are 2789 resources available
1306P - Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
Presenter: Atsushi Nakamura
Session: ePoster Display
1307P - Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
Presenter: Yasushi Goto
Session: ePoster Display
1257P - Effect of hepatic impairment on tepotinib pharmacokinetics
Presenter: Thomas Marbury
Session: ePoster Display
1259P - Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
Presenter: Xiuning Le
Session: ePoster Display
1260P - Clinical outcomes of patients with BRAF<sup>v</sup>⁶⁰⁰-mutated metastatic NSCLC (mNSCLC) receiving first-line (1L) dabrafenib-trametinib vs other standard of care in real-world practice
Presenter: Barbara Melosky
Session: ePoster Display
1312P - Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy
Presenter: Giacomo Pelizzari
Session: ePoster Display
1262P - ROS1 resistance mutations and co-occurring genetic alterations to the ROS1 protein-tyrosine kinase inhibitors (crizotinib) in lung cancer
Presenter: Yuqing Weng
Session: ePoster Display
1380P - Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
Presenter: Geoffrey Ku
Session: ePoster Display